Developer docs
API playgroundTry for free, no card

Search company profiles

Century Therapeutics

Full company profile

uuid00004ku

Namestring
Century Therapeutics
Legal namestring
Century Therapeutics, Inc.
Websiteurl
centurytx.com
Company typeenum
Public
Founded yearint
2018
Descriptiontext

Century Therapeutics is a Philadelphia-based, NASDAQ-listed (IPSC) clinical-stage biotechnology company founded in 2018 that develops allogeneic, induced pluripotent stem cell (iPSC)-derived cell therapies targeting autoimmune diseases — including Type 1 Diabetes and B-cell-mediated autoimmune diseases — and hematologic and solid tumor cancers. The proprietary platform integrates CRISPR-MAD7 gene editing for precise knock-in and knock-out without random integration, common engineered iPSC progenitor cells, a Cell Foundry differentiation process, and Allo-Evasion™ immune evasion technology (versions 1.0 and 5.0) intended to avoid host immune rejection and enable repeat dosing without intensive preconditioning. The product portfolio comprises CNTY-813 (iPSC-derived beta islet cells for Type 1 Diabetes, IND targeted for Q4 2026), CNTY-308 (CD19-targeted CAR-iT cells for B-cell-mediated autoimmune diseases, entering clinical trials in 2026), CNTY-101 (CAR-iNK cells for B-cell-mediated autoimmune diseases in an investigator-sponsored trial at Friedrich-Alexander University Erlangen-Nürnberg), and the platform itself; a manufacturing sublicense and technology base developed from prior acquisitions of Empirica Therapeutics (2020) and Clade Therapeutics (April 2024).

The business model is pre-commercial products with revenue generated entirely through a strategic collaboration with Bristol-Myers Squibb, which produced $109.2M of collaboration revenue in Q1 2025 versus $6.6M in the prior-year period and zero collaboration revenue in Q1 2026. Distribution occurs through company-sponsored and investigator-sponsored clinical trials at research hospitals and specialty centers, with future commercialization expected to target hospitals and specialty clinics serving oncology and autoimmune disease patients. Operations are funded by equity: a $250M Series B (2019), $160M Series C (2021), $150M strategic investment from Bristol-Myers Squibb (2022), a $60M private placement (April 2024), and a $135M oversubscribed private placement in January 2026 that, together with a $150M ATM program and $217M cash and equivalents at March 31, 2026, funds operations into Q1 2029. Century employed 101-250 staff as of the most recent disclosure and reported a $21.6M net loss for Q1 2026.

Short descriptiontext

Century Therapeutics is a clinical-stage biotechnology company that develops allogeneic, iPSC-derived cell therapies — including CNTY-813 for Type 1 Diabetes and CNTY-101, CNTY-308, and CARAMEL for B-cell-mediated autoimmune diseases and oncology — and is funded through its Bristol-Myers Squibb collaboration and equity financings.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersPhiladelphia, United States
HQ citystring
Philadelphia
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
allogeneic cell therapy, iPSC-derived therapies, autoimmune disease treatment, oncology cell therapy, gene edited cell therapies
Industry2 codes
PRIMARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Cell Therapy
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Collaboration Revenue
TypeLicensing Royalties
Description

Revenue from strategic collaborations with pharmaceutical partners, including collaboration agreements for development activities. Historical collaboration revenue of $109.2 million from Bristol-Myers Squibb in Q1 2025, compared to $6.6 million in the prior year period. No collaboration revenue in Q1 2026.

globenewswire.com
2Future Product Revenue
TypeOne Time License
Description

Pre-revenue clinical stage company. No commercialized products. Future revenue will come from potential FDA-approved cell therapy products for autoimmune diseases and cancer upon successful completion of clinical trials and regulatory approval.

globenewswire.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Century Therapeutics develops allogeneic, induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases (including Type 1 Diabetes) and cancer. Its pipeline candidates (CNTY-813, CNTY-308, CNTY-101, CARAMEL IST) are engineered with proprietary Allo-Evasion™ immune evasion technology and CRISPR-MAD7 gene editing to enable off-the-shelf, redosable therapies manufactured from a single iPSC clone master cell bank. The company is pre-revenue, generates collaboration revenue (notably from Bristol-Myers Squibb), and targets commercial distribution through hospitals and specialty clinics upon regulatory approval.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • CNTY-813 demonstrated sustained glucose control for more than eight months in preclinical mouse models without chronic immunosuppression
+3 more records
Product overview1 text field

Century Therapeutics is a biotechnology company developing an industry-leading allogeneic, iPSC-derived cell therapy platform for autoimmune diseases (including Type 1 Diabetes) and cancer. The company's product portfolio consists of multiple clinical and preclinical candidates: CNTY-813 (iPSC-derived beta islet cells for Type 1 Diabetes), CNTY-308 (CD19-targeted CAR-iT cells for B-cell-mediated autoimmune diseases), CNTY-101 (CAR-iNK cells for B-cell-mediated autoimmune diseases), and CARAMEL IST (iT cells for autoimmune diseases and solid tumors). All product candidates incorporate the proprietary Allo-Evasion™ immune evasion technology. The platform is built on iPSC cell foundry capabilities that leverage CRISPR-MAD7 gene editing, CAR and protein engineering, and common engineered iPSC progenitors to generate a consistent, scalable manufacturing process.

Product and service4 records
1CNTY-813
CategoryCell Therapy - Autoimmune
Description

iPSC-derived beta islet cell therapy engineered with Allo-Evasion™ 5.0 technology, designed to protect from T cell, NK cell, and humoral immune rejection for durable glycemic control without systemic immunosuppression. Being developed as a potential functional cure for Type 1 Diabetes.

2CNTY-308
CategoryCell Therapy - Autoimmune
Description

CD19-targeted CD4+/CD8+ αβ CAR-iT cell therapy engineered with Allo-Evasion™ 5.0, functionally comparable to primary T cells. Being developed as a potential treatment for B-cell-mediated autoimmune diseases.

3CNTY-101
CategoryCell Therapy - Autoimmune
Description

CAR-iNK cell therapy with six precision gene edits, incorporating Allo-Evasion™ 1.0 technology. Being developed as a potential treatment for patients with B-cell-mediated autoimmune diseases.

4CARAMEL IST
CategoryCell Therapy - Autoimmune/Oncology
Description

iT cell therapy engineered with Allo-Evasion™ 5.0, being developed for B-cell-mediated autoimmune diseases, solid tumors, and other indications under an investigator-sponsored trial by researchers at Friedrich-Alexander University Erlangen-Nürnberg.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Bristol-Myers Squibb
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Strategic collaboration with Bristol-Myers Squibb for cell therapy development. Collaboration revenue was $109.2 million in Q1 2025 compared to $6.6 million in prior year period, reflecting milestone payments and development activities under the partnership agreement.

finance.yahoo.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-04-11
Description

Acquired by Century Therapeutics in April 2024 to enhance pipeline and platform capabilities. Clade Therapeutics was a privately-held cell therapy company focused on iPSC-derived αβ T cell programs and technology spanning cancer and autoimmune diseases, founded by Chad Cowan.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Investigator-sponsored trial (IST) for CNTY-101 being conducted by Professors Georg Schett and Andreas Mackensen at Friedrich-Alexander University Erlangen-Nürnberg for B-cell-driven autoimmune diseases.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Fate Therapeutics is the closest direct peer — also developing iPSC-derived off-the-shelf NK and T-cell therapies (iPSC platform with engineered CD16, CAR, TCR, and antigen receptor constructs). Competes head-to-head in allogeneic, off-the-shelf cell therapy with similar target indications in oncology and increasingly autoimmune disease.

TypeDirect peer
Description

Allogene is a leading allogeneic CAR-T developer with multiple clinical-stage candidates targeting hematologic malignancies. Direct competitor in the allogeneic cell therapy space with similar manufacturing scale-up ambitions and a broader clinical pipeline than Century.

TypeDirect peer
Description

Atara develops allogeneic T-cell immunotherapies, including EBV-specific T cells and CAR-T programs. Directly comparable as an allogeneic, off-the-shelf cell therapy developer with overlapping autoimmune and oncology indications.

TypeDirect peer
Description

Cellectis is a clinical-stage gene-edited allogeneic CAR-T developer using TALEN-based gene editing. Comparable as an allogeneic platform company targeting hematologic malignancies with similar enabling technology (gene editing + allogeneic cell therapy).

TypeDirect peer
Description

Caribou develops allogeneic CAR-T cell therapies using CRISPR-based gene editing (similar enabling technology to Century's CRISPR-MAD7). Direct peer in the allogeneic CAR-T space with clinical-stage assets.

TypeDirect peer
Description

Precision BioSciences develops allogeneic CAR-T therapies using its proprietary ARCUS gene editing platform. Comparable as a gene-editing-enabled allogeneic cell therapy company with oncology and emerging autoimmune indications.

TypeEmerging player
Description

Sana is developing hypoimmune-modified iPSC-derived cell therapies to evade immune rejection — a directly comparable technological approach to Century's Allo-Evasion™. Founded by Chad Cowan (Century's CSO) before he moved to Century, creating a direct scientific lineage connection.

TypeEmerging player
Description

CRISPR Therapeutics is a leading gene editing company co-founded by Chad Cowan (Century's CSO) that is also developing gene-edited cell therapies (including Casgevy, the first approved CRISPR-based therapy). Relevant peer given shared scientific lineage, gene editing platform overlap, and cell therapy ambitions.

TypeBroad incumbent
Description

Vertex is advancing zimislecel (acquired via ViaCyte), a stem cell-derived islet cell therapy for Type 1 Diabetes, putting it in direct competition with Century's CNTY-813 lead program. Far larger and more resourced incumbent in the T1D cell therapy space.

TypeDirect peer
Description

Adaptimmune develops engineered T-cell therapies (SPEAR T-cells) for solid tumors and is expanding into autoimmune indications. Comparable as a cell therapy developer with platform-level manufacturing capabilities and overlapping therapeutic focus areas.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors26 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Century Therapeutics

Cell Therapycenturytx.com

Century Therapeutics is a clinical-stage biotechnology company that develops allogeneic, iPSC-derived cell therapies — including CNTY-813 for Type 1 Diabetes and CNTY-101, CNTY-308, and CARAMEL for B-cell-mediated autoimmune diseases and oncology — and is funded through its Bristol-Myers Squibb collaboration and equity financings.

What Century Therapeutics does

Century Therapeutics is a Philadelphia-based, NASDAQ-listed (IPSC) clinical-stage biotechnology company founded in 2018 that develops allogeneic, induced pluripotent stem cell (iPSC)-derived cell therapies targeting autoimmune diseases — including Type 1 Diabetes and B-cell-mediated autoimmune diseases — and hematologic and solid tumor cancers. The proprietary platform integrates CRISPR-MAD7 gene editing for precise knock-in and knock-out without random integration, common engineered iPSC progenitor cells, a Cell Foundry differentiation process, and Allo-Evasion™ immune evasion technology (versions 1.0 and 5.0) intended to avoid host immune rejection and enable repeat dosing without intensive preconditioning. The product portfolio comprises CNTY-813 (iPSC-derived beta islet cells for Type 1 Diabetes, IND targeted for Q4 2026), CNTY-308 (CD19-targeted CAR-iT cells for B-cell-mediated autoimmune diseases, entering clinical trials in 2026), CNTY-101 (CAR-iNK cells for B-cell-mediated autoimmune diseases in an investigator-sponsored trial at Friedrich-Alexander University Erlangen-Nürnberg), and the platform itself; a manufacturing sublicense and technology base developed from prior acquisitions of Empirica Therapeutics (2020) and Clade Therapeutics (April 2024).

The business model is pre-commercial products with revenue generated entirely through a strategic collaboration with Bristol-Myers Squibb, which produced $109.2M of collaboration revenue in Q1 2025 versus $6.6M in the prior-year period and zero collaboration revenue in Q1 2026. Distribution occurs through company-sponsored and investigator-sponsored clinical trials at research hospitals and specialty centers, with future commercialization expected to target hospitals and specialty clinics serving oncology and autoimmune disease patients. Operations are funded by equity: a $250M Series B (2019), $160M Series C (2021), $150M strategic investment from Bristol-Myers Squibb (2022), a $60M private placement (April 2024), and a $135M oversubscribed private placement in January 2026 that, together with a $150M ATM program and $217M cash and equivalents at March 31, 2026, funds operations into Q1 2029. Century employed 101-250 staff as of the most recent disclosure and reported a $21.6M net loss for Q1 2026.

Century Therapeutics firmographics

Firmographics
Name
Century Therapeutics
Legal name
Century Therapeutics, Inc.
Website
https://centurytx.com
Company type
Public
Founded year
2018
Operating status
Operating
Headcount range
101–250 employees
Short description
Century Therapeutics is a clinical-stage biotechnology company that develops allogeneic, iPSC-derived cell therapies — including CNTY-813 for Type 1 Diabetes and CNTY-101, CNTY-308, and CARAMEL for B-cell-mediated autoimmune diseases and oncology — and is funded through its Bristol-Myers Squibb collaboration and equity financings.
Ownership category
akta.pro rank

Century Therapeutics industry classification

Industry
Product category
Cell Therapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Allogeneic cell therapy
  • IPSC-derived therapies
  • Autoimmune disease treatment
  • Oncology cell therapy
  • Gene edited cell therapies

Where Century Therapeutics is headquartered

Location

Headquarters

HQ city
Philadelphia
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Century Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure

Revenue model

  1. Collaboration Revenue: Revenue from strategic collaborations with pharmaceutical partners, including collaboration agreements for development activities. Historical collaboration revenue of $109.2 million from Bristol-Myers Squibb in Q1 2025, compared to $6.6 million in the prior year period. No collaboration revenue in Q1 2026.
  2. Future Product Revenue: Pre-revenue clinical stage company. No commercialized products. Future revenue will come from potential FDA-approved cell therapy products for autoimmune diseases and cancer upon successful completion of clinical trials and regulatory approval.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Century Therapeutics product offering

Product offering

Core offering

Century Therapeutics develops allogeneic, induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases (including Type 1 Diabetes) and cancer. Its pipeline candidates (CNTY-813, CNTY-308, CNTY-101, CARAMEL IST) are engineered with proprietary Allo-Evasion™ immune evasion technology and CRISPR-MAD7 gene editing to enable off-the-shelf, redosable therapies manufactured from a single iPSC clone master cell bank. The company is pre-revenue, generates collaboration revenue (notably from Bristol-Myers Squibb), and targets commercial distribution through hospitals and specialty clinics upon regulatory approval.

Product overview

Century Therapeutics is a biotechnology company developing an industry-leading allogeneic, iPSC-derived cell therapy platform for autoimmune diseases (including Type 1 Diabetes) and cancer. The company's product portfolio consists of multiple clinical and preclinical candidates: CNTY-813 (iPSC-derived beta islet cells for Type 1 Diabetes), CNTY-308 (CD19-targeted CAR-iT cells for B-cell-mediated autoimmune diseases), CNTY-101 (CAR-iNK cells for B-cell-mediated autoimmune diseases), and CARAMEL IST (iT cells for autoimmune diseases and solid tumors). All product candidates incorporate the proprietary Allo-Evasion™ immune evasion technology. The platform is built on iPSC cell foundry capabilities that leverage CRISPR-MAD7 gene editing, CAR and protein engineering, and common engineered iPSC progenitors to generate a consistent, scalable manufacturing process.

Differentiator

Problem solved

Functional benefit

Products and services

  • CNTY-813 iPSC-derived beta islet cell therapy engineered with Allo-Evasion™ 5.0 technology, designed to protect from T cell, NK cell, and humoral immune rejection for durable glycemic control without systemic immunosuppression. Being developed as a potential functional cure for Type 1 Diabetes.
  • CNTY-308 CD19-targeted CD4+/CD8+ αβ CAR-iT cell therapy engineered with Allo-Evasion™ 5.0, functionally comparable to primary T cells. Being developed as a potential treatment for B-cell-mediated autoimmune diseases.
  • CNTY-101 CAR-iNK cell therapy with six precision gene edits, incorporating Allo-Evasion™ 1.0 technology. Being developed as a potential treatment for patients with B-cell-mediated autoimmune diseases.
  • CARAMEL IST iT cell therapy engineered with Allo-Evasion™ 5.0, being developed for B-cell-mediated autoimmune diseases, solid tumors, and other indications under an investigator-sponsored trial by researchers at Friedrich-Alexander University Erlangen-Nürnberg.

Quantifiable outcome

  • CNTY-813 demonstrated sustained glucose control for more than eight months in preclinical mouse models without chronic immunosuppression
  • +3 more outcomes

Companies that use Century Therapeutics

Customer profile

Segments3 records

Ideal customer profiles2 records

Century Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Century Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered major and core.

  • Bristol-Myers SquibbmajorStrategic or Co-development Partner · 1 January 2025Strategic collaboration with Bristol-Myers Squibb for cell therapy development. Collaboration revenue was $109.2 million in Q1 2025 compared to $6.6 million in prior year period, reflecting milestone payments and development activities under the partnership agreement.
  • Clade TherapeuticsmajorStrategic or Co-development Partner · 11 April 2024Acquired by Century Therapeutics in April 2024 to enhance pipeline and platform capabilities. Clade Therapeutics was a privately-held cell therapy company focused on iPSC-derived αβ T cell programs and technology spanning cancer and autoimmune diseases, founded by Chad Cowan.
  • Friedrich-Alexander University Erlangen-NürnbergcoreStrategic or Co-development PartnerInvestigator-sponsored trial (IST) for CNTY-101 being conducted by Professors Georg Schett and Andreas Mackensen at Friedrich-Alexander University Erlangen-Nürnberg for B-cell-driven autoimmune diseases.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Century Therapeutics competitors and assessment

Company assessment

Direct peers

  • Fate Therapeutics: Fate Therapeutics is the closest direct peer — also developing iPSC-derived off-the-shelf NK and T-cell therapies (iPSC platform with engineered CD16, CAR, TCR, and antigen receptor constructs). Competes head-to-head in allogeneic, off-the-shelf cell therapy with similar target indications in oncology and increasingly autoimmune disease.
  • Allogene Therapeutics: Allogene is a leading allogeneic CAR-T developer with multiple clinical-stage candidates targeting hematologic malignancies. Direct competitor in the allogeneic cell therapy space with similar manufacturing scale-up ambitions and a broader clinical pipeline than Century.
  • Atara Biotherapeutics: Atara develops allogeneic T-cell immunotherapies, including EBV-specific T cells and CAR-T programs. Directly comparable as an allogeneic, off-the-shelf cell therapy developer with overlapping autoimmune and oncology indications.
  • Cellectis: Cellectis is a clinical-stage gene-edited allogeneic CAR-T developer using TALEN-based gene editing. Comparable as an allogeneic platform company targeting hematologic malignancies with similar enabling technology (gene editing + allogeneic cell therapy).
  • Caribou Biosciences: Caribou develops allogeneic CAR-T cell therapies using CRISPR-based gene editing (similar enabling technology to Century's CRISPR-MAD7). Direct peer in the allogeneic CAR-T space with clinical-stage assets.
  • Precision BioSciences: Precision BioSciences develops allogeneic CAR-T therapies using its proprietary ARCUS gene editing platform. Comparable as a gene-editing-enabled allogeneic cell therapy company with oncology and emerging autoimmune indications.
  • Adaptimmune Therapeutics: Adaptimmune develops engineered T-cell therapies (SPEAR T-cells) for solid tumors and is expanding into autoimmune indications. Comparable as a cell therapy developer with platform-level manufacturing capabilities and overlapping therapeutic focus areas.

Emerging players

  • Sana Biotechnology: Sana is developing hypoimmune-modified iPSC-derived cell therapies to evade immune rejection — a directly comparable technological approach to Century's Allo-Evasion™. Founded by Chad Cowan (Century's CSO) before he moved to Century, creating a direct scientific lineage connection.
  • CRISPR Therapeutics: CRISPR Therapeutics is a leading gene editing company co-founded by Chad Cowan (Century's CSO) that is also developing gene-edited cell therapies (including Casgevy, the first approved CRISPR-based therapy). Relevant peer given shared scientific lineage, gene editing platform overlap, and cell therapy ambitions.

Broad incumbents

  • Vertex Pharmaceuticals: Vertex is advancing zimislecel (acquired via ViaCyte), a stem cell-derived islet cell therapy for Type 1 Diabetes, putting it in direct competition with Century's CNTY-813 lead program. Far larger and more resourced incumbent in the T1D cell therapy space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Century Therapeutics social profiles

Digital presence

Century Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Century Therapeutics leadership team

Management profile

Number of profiles

Profiles7 records

Century Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Century Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors26 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Century Therapeutics M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Century Therapeutics

What does Century Therapeutics do?

Century Therapeutics develops allogeneic, induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases (including Type 1 Diabetes) and cancer. Its pipeline candidates (CNTY-813, CNTY-308, CNTY-101, CARAMEL IST) are engineered with proprietary Allo-Evasion™ immune evasion technology and CRISPR-MAD7 gene editing to enable off-the-shelf, redosable therapies manufactured from a single iPSC clone master cell bank. The company is pre-revenue, generates collaboration revenue (notably from Bristol-Myers Squibb), and targets commercial distribution through hospitals and specialty clinics upon regulatory approval.

Is Century Therapeutics a public or private company?

Century Therapeutics is a public company. It is classified as public and is currently operating.

When was Century Therapeutics founded?

Century Therapeutics was founded in 2018. It employs 101 to 250 people.

Where is Century Therapeutics based?

Century Therapeutics is headquartered in Philadelphia, United States, in the North America region.

How does Century Therapeutics make money?

Two revenue lines are on record. Collaboration Revenue is the primary driver. The others are future Product Revenue.

Who are Century Therapeutics's main competitors?

Direct peers on record are Fate Therapeutics, Allogene Therapeutics, Atara Biotherapeutics, Cellectis, Caribou Biosciences, Precision BioSciences and Adaptimmune Therapeutics. Emerging players are Sana Biotechnology and CRISPR Therapeutics. Vertex Pharmaceuticals is listed as a broad incumbent.

Does Century Therapeutics have an API?

No public API is recorded for Century Therapeutics.

What industry is Century Therapeutics in?

Century Therapeutics's product category is Cell Therapy. Its primary akta.pro industry code is HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf), with a secondary code of HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewCentury Therapeutics Reports Q3 2026 Loss of $23.5 Million, Cash of $174.1 MillionCentury Therapeutics reported a Q3 2026 net loss of $23.5 million, down from $34.4 million a year earlier, with cash of $174.1 million. R&D expenses fell to $18.1 million, and the company expects its cash runway to extend into Q1 2029.Quiver QuantitativeCentury Therapeutics Reports $23.5 Million Third-Quarter Net Loss | IPSC Stock NewsCentury Therapeutics reported a third-quarter 2026 net loss of $23.5 million, down from $34.4 million a year earlier, with zero collaboration revenue. The company held $174.1 million in cash and investments, extending its runway to the first quarter of 2029. Its CNTY-813 program remains on track for an IND submission in Q4 2026.American Banking and Market NewsCentury Therapeutics, Inc. (NASDAQ:IPSC) Stock Rated “Hold” by Wall Street BrokeragesWall Street brokerages rate Century Therapeutics with an average "Hold" recommendation, with one sell, two holds, and four buys. The average 12-month price target is $4.75, and the stock opened at $1.74. The company missed Q2 earnings estimates with a -$0.17 EPS versus -$0.11 expected.American Banking and Market NewsCentury Therapeutics (IPSC) Expected to Release Quarterly Earnings on ThursdayCentury Therapeutics is expected to release Q3 2026 earnings on Thursday, November 12th, with analysts projecting a loss of $0.12 per share and revenue of $1.63 million. The stock opened at $1.68, down 7.2% from Wednesday, and the company has an average analyst rating of Hold with a consensus target price of $4.75.MarketBeatCentury Therapeutics (NASDAQ:IPSC) Cut to "Sell" at Wall Street ZenWall Street Zen downgraded Century Therapeutics from Hold to Sell, while Weiss Ratings restated a Sell rating. The company reported Q2 EPS of -$0.17, missing the -$0.11 consensus estimate. Analysts have a consensus Hold rating with an average target price of $4.75.American Banking and Market NewsCentury Therapeutics (NASDAQ:IPSC) Rating Lowered to “Sell” at Wall Street ZenWall Street Zen downgraded Century Therapeutics from 'hold' to 'sell' on Saturday. The stock has a consensus 'Hold' rating with a $4.75 price target, and the company reported a loss of $0.17 per share for the quarter, missing estimates. Institutional investors own 50.20% of the company.Markets DailyDenali Therapeutics (NASDAQ:DNLI) vs. Century Therapeutics (NASDAQ:IPSC) Head-To-Head ContrastDenali Therapeutics and Century Therapeutics are compared on earnings, valuation, and analyst recommendations. Century Therapeutics has a higher consensus price target ($4.75 vs $35.85) and beats Denali on 7 of 12 factors, though Denali trades at a lower P/E. Analysts favor Century due to its higher probable upside.Stock TitanCentury Therapeutics to Attend Jefferies Conference Nov. 18Century Therapeutics will attend the 2026 Jefferies Global Healthcare Conference in London on November 18, 2026. The company, which develops iPSC-derived cell therapies for type 1 diabetes and other autoimmune diseases, invites attendees to request 1x1 meetings with its team.MarketBeatCentury Therapeutics, Inc. (NASDAQ:IPSC) Stock Has Consensus Target Price of $4.75Century Therapeutics has a consensus 'Hold' rating with an average 12-month target price of $4.75 from seven analysts. The stock opened at $1.44, with a one-year range of $0.43 to $3.04, and 50.2% institutional ownership. Analysts forecast a loss of $0.51 per share for the current year.Markets DailyCentury Therapeutics (NASDAQ:IPSC) vs. Burning Rock Biotech (NASDAQ:BNR) Head to Head ContrastCentury Therapeutics and Burning Rock Biotech are compared on valuation, ratings, and ownership. Century Therapeutics has a stronger consensus rating, higher institutional ownership, and a 223% upside target, beating Burning Rock on 9 of 14 factors.